ArticleJournal of thoracic disease2011
New molecular targeted therapies for advanced non-small-cell lung cancer.
Article in Journal of thoracic disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer.Cell death & disease · 2024Article
- Chitinase 3 like 1 suppresses the stability and activity of p53 to promote lung tumorigenesis.Cell communication and signaling : CCS · 2020Article
- Combinational Effect ofBioMed research international · 2018Article
- Effects of silencing Rab27a gene on biological characteristics and chemosensitivity of non-small cell lung cancer.Oncotarget · 2017Article
- cDNA microarray analysis of the effect of cantharidin on DNA damage, cell cycle and apoptosis-associated gene expression in NCI-H460 human lung cancer cells in vitro.Molecular medicine reports · 2015Article
- Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growthOncology letters · 2014Article
- Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.BMC complementary and alternative medicine · 2014Article
- Medicinal Plants and Other Living Organisms with Antitumor Potential against Lung Cancer.Evidence-based complementary and alternative medicine : eCAM · 2014Review
- Loss of ARHI expression in colon cancer and its clinical significance.Contemporary oncology (Poznan, Poland) · 2014Article
- Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro.Molecular biology reports · 2013Article
- Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013Article
- Effect of targeted silencing of hTERT mRNA by lentivirus-mediated siRNA on A549 lung cancer cells in vitro.Molecular biology reports · 2013Article
- Effects of BTG2 on proliferation inhibition and anti-invasion in human lung cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- The expression and clinical significance of CLIC1 and HSP27 in lung adenocarcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.Cancers · 2011Article
- Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)?Journal of thoracic disease · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancer (NSCLC) is a uniformly fatal disease and most patients will present with advanced stage. Treatment outcomes remain unsatisfactory, with low long-term survival rates. Standard treatment, such as palliative chemotherapy and radiotherapy, offers a median survival not exceeding 1 year. Hence, considerable efforts have started to be made in order to identify new biological agents which may safely and effectively be administered to advanced NSCLC patients. Two cancer cell pathways in particular have been exploited, the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor receptor (VEGFR) pathways. However, novel targeted therapies that interfere with other dysregulated pathways in lung cancer are already in the clinic. This review outlines the most promising research approaches to the treatment of NSCLC, discussed according to the specific molecular pathway targeted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.